it is unlikely that randomized clinical trials will ever be possible, e.g., in defining the role of inferior vena cava filters or of pulmonary thrombectomy. It is our hope that the following articles will identify areas in which evidence-based recommendations can be made, as well as the various areas that require further clinical trials. We also hope that the presentations will stimulate some debate regarding the controversies and perhaps result in the submission of Letters to the Editor. Drs should be taken to ensure that all patients are maintained within the therapeutic INR most or all of the time. At present it is not known how many laboratories and hospitals report INRs exclusively, and it is probably time for ' Dr. Bussey and for the Thrombosis Interest Group in Canada to repeat their surveys. It is also strongly recommended that in the reporting of clinical trials, INR specific events be reported as a function of time.
The extensive studies relating to the role of anticoagu-lant treatment in the prevention of vascular events after PTCA and coronary stent placement are reviewed by Dr. Kugelmass and Mr. Raskob, with the application of levels of evidence to the data wherever possible. They conclude with a list of recommendations that should stimulate some debate. Although unfractionated heparin and aspirin clearly have an established role, the use of the new platelet inhibitors and low molecular weight (LMW) heparin is of particular interest. To date, the specific thrombin inhibitors have been disappointing. Dr. Elliott discusses the dinical trials comparing thrombolysis with heparin and comparative studies with different thrombolytic agents in patients with acute pulmonary embolism. He identifies some of the reasons why a mortality difference has not been identified. In particular, it will be difficult to identify a mortality benefit in the majority of patients who meet the usual inclusion and exclusion criteria for clinical trials and, to do so, such studies will have to be very large. It may be necessary to admit patients with acute massive pulmonary emboli who have significant co-morbid conditions, who have relative contraindications to thrombdlysis, and who may not be able to undergo the usual confirmatory tests for pulmonary embolism. In the latter regard, two dimensionat echocardiography may permit such patients to . enter ~clini~al trials. In the meantime, the aggressive use of heparin or LMW heparin will remain the treatment of choice, with thrombolysis being used in carefully selected patients.
The ~iterattare on the chemical and phaz7m~~c~Ic~g~c properties of the LMW heparins is reviewed by Dr. Fareed and colleagues from Loyola University. They add a number of comparative studies of their own. They provide convincmug evidence that these agents must continue to be tested separately in the various clinical' settings. Outcome results in the prevention of venous thrombosis after various general surgical or orthopedic procedures are very similar, suggesting that at the lower doses the outcome differences with the various LMW heparins may have little relevance. However, when higher doses are used for treatment of venous or arterial thrombotic disease it is likely that the differences in clinical outcomes with respect to recurrent S7 thrombosis and to hemorrhagic side effects will be exaggerated. Furthermore, the role of various mediators, such as tissue factor pathway inhibitor and heparin co-factor 11, may be quite different with the higher-dose therapy. Dr. Fareed and colleagues conclude their ~icl~ by indicating that &dquo;a collective statement based on the performance of LMW heparins as a group must be based on valid meta-an~.lyses*&dquo; Having provided such a convincing argument that all of the LMW heparins are different, it may not be logical to analyze outcome studies by metaanalyses other than to develop hypotheses for future trials.
Dr. Walenga and colleagues review the syndromes of heparin-induced ~hrc~ml~ocytc~penia, including the available information on pathogencsis and treatment. We are still left with an uneasy feeling that heparin-induced thrombocytopenia represents a variety of pathogenic mechanisms that may require a variety of diagnostic tests to establish a firm diagnosis. To date, the serotonin release assay has had the highest sensitivity and specificity, but this has not been the universal experience. There is still a need for a simple assay that can be more widely applied. The specific antithrombin agents, indeed, hold the greatest promise for the treatment of this syndrome, and a large clinical trial with use of Argatroban is now under way in North America. The results of this study will be awaited with interest.
Drs. Anand, Ginsbe rg, and Hirsh reviewed the data from clinical trials indicating that inadequate intravenous heparin in the initial 24-48 h predisposed to an increased incidence of recurrent thromboembolism when compared with patients who received adequate heparin treatment with respect to APTT levels. Their overview suggested that the risk of recurrent deep vein thrombosis was not increased in patients who were subtherapeutic early (e.g., for the first 24-48 h). The conclusion of this overview is refuted by four Ievel-I studies indicating the need for rapid therapeutic anticoagulation and by the studies evaluating the protocols.
Finally, in our review of the treatment of venous thromboembolism we have compared the management of this disorder in the past with the current approach to treatment. For the most part, current management is based on the results of level I clinical trials. Where it is not possible to make evidence-based recommendations, it is necessary to resort to clinical intuition or to extrapolation from similar clinical settings. Fortunately for the practicing physician, there are a number of clinical trials currently under way that should fill in some of the gaps in our knowledge.
